Primary Care Clinics in Owatonna, MN Accepting Medicare
5 Primary Care Clinics found. Showing 1 - 5
 Mayo Clinic Health System-owatonna Clinic/Center - Multi-Specialty Medicare: Not Enrolled in Medicare Practice Location: 2200 Nw 26th St, Owatonna, MN 55060 Phone: 507-451-1120 |
Mcr, Iris Park Chiropractic Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 1828 S Cedar Ave # 2, Owatonna, MN 55060 Phone: 507-451-9155 |
Owatonna Natural Health Clinic Inc. Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 152 E Pearl St, Owatonna, MN 55060 Phone: 507-451-1691 |
Via Orthopedics, Llc Clinic/Center Medicare: Medicare Enrolled Practice Location: 202 N Cedar Ave Ste 1, Owatonna, MN 55060 Phone: 615-714-5953 |
Chiropractic Care Of Owatonna Llc Clinic/Center - Primary Care Medicare: Not Enrolled in Medicare Practice Location: 605 Hillcrest Ave Ste 120, Owatonna, MN 55060 Phone: 507-214-2584 |
News Archive
Helicos Biosciences to raise $10 million through private placement
Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets, today announced that it has entered into a definitive agreement with certain new and existing investors, including Atlas Ventures, Flagship Ventures, Highland Capital Partners, Versant Ventures (the "Existing Investors") and Ron Lowy, the Company's chief executive officer, to raise approximately $10 million in gross proceeds in a private placement through the sale of shares of its common stock and warrants.
Traceability Institute discusses U.S. food safety system at FDA and FSIS joint public meeting
Traceability Institute Partner and Founder Cristian Barcan provides comment on improving the food safety system during today's joint public meeting of the Food and Drug Administration (FDA) and Food Safety and Inspection Service (FSIS) in Washington, DC.
Gene alterations associated with response to anthracycline therapy for breast cancer
Alterations in the topoisomerase II alpha (TOP2A) gene were associated with better patient outcomes following anthracycline-based therapy compared with non-anthracycline-based regimens, according to a study in the April 28 online issue of the Journal of the National Cancer Institute.
Genetic Analysis and Bio-Rad enter into supply and distribution agreement for GA-map clinical test
Genetic Analysis and Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products, today announced that they have signed a supply and distribution agreement for Genetic Analysis's GA-map™ clinical test for gut dysbiosis.
Courtagen, AGBL enter exclusive distribution agreement for clinical tests
Courtagen Life Sciences Inc. announced today they have signed an exclusive strategic distribution agreement with the Alliance Global Group (AGBL) to help clinicians in emerging markets diagnose and manage a number of genetically based disorders.
› Verified 2 days ago